Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma-Reference-Cited by-同舟云学术

Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma

Published:2024-06-10 Issue: Volume: Page:1-9
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Chang Julie E.¹,Wang Tuo²,Kim KyungMann²,Folstad Matthew¹,Endres Mariah³,Howard Mitch³,Kenkre Vaishalee¹,Fletcher Christopher¹,Rajguru Saurabh¹

Affiliation:

1. Department of Medicine, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, Madison, WI, USA

2. Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, USA

3. Carbone Cancer Center, University of Wisconsin Hospital and Clinics, Madison, WI, USA

Funder

Genentech

Cancer Center Support Grant

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2360535

Reference30 articles.

1. First-line chemo immunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial;Eichhorst B;Lancet Oncol,2016

2. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

3. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

4. Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

5. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma